Vutrisiran
AMVUTTRA
- Dosage form
- Tablet
- Available strengths
- 25 mg/0.5 mL
- Drug class
- Small interfering RNA (siRNA) therapy, transthyretin (TTR)-directed gene silencer
- Common brand
- AMVUTTRA
Clinical overview. Vutrisiran is a small interfering RNA (siRNA) therapeutic (brand name AMVUTTRA) given by subcutaneous injection to treat polyneuropathy or cardiomyopathy caused by hereditary or wild-type transthyretin (TTR) amyloidosis. It works by reducing liver production of the TTR protein that forms harmful amyloid deposits in nerves and heart tissue. Because lowering TTR also lowers blood vitamin A levels, daily vitamin A supplementation and monitoring for eye-related deficiency symptoms are required throughout treatment, and effective contraception is needed due to the teratogenic risk of unbalanced vitamin A levels.
Indication
Common therapeutic uses
- Vutrisiran (AMVUTTRA) is used to treat stage 1 or stage 2 polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis).
- Vutrisiran is also used to treat cardiomyopathy in adults with wild-type or hereditary transthyretin amyloidosis (wtATTR or hATTR amyloidosis).
- Treatment should be started as early as possible in the disease course to help prevent the buildup of disability.
Pregnancy
Risk assessment and monitoring considerations
- There are no data on vutrisiran use in pregnant women, and the effects of reduced maternal TTR or vitamin A levels on the fetus are unknown.
- Vutrisiran is not recommended during pregnancy, since both too-high and too-low vitamin A levels during early pregnancy may increase the risk of fetal malformation.
- Pregnancy should be ruled out before starting treatment, and women of childbearing potential should use effective contraception during treatment.
- If pregnancy is planned, vutrisiran and vitamin A supplementation should be stopped, and serum vitamin A levels monitored until they return to normal before conception is attempted.
- If pregnancy occurs unexpectedly during treatment, vutrisiran should be discontinued.
- There are no human data on vutrisiran's effect on fertility; animal studies showed no impact on male or female fertility.
Breastfeeding
Infant exposure considerations
- It is not known whether vutrisiran passes into human breast milk or affects milk production.
- Breast milk is an important source of vitamin A for infants, and vutrisiran's effect on vitamin A levels in breast milk has not been studied.
- The benefits of breastfeeding should be weighed against the mother's clinical need for treatment and any potential risk to the infant.
Geriatrics
Dosing and tolerability considerations
- No overall differences in safety or effectiveness were observed between patients 65 years of age or older and younger patients, though greater sensitivity in some older individuals cannot be ruled out.
- No dose adjustment is required based on age alone.
- A substantial proportion of patients in the polyneuropathy and cardiomyopathy clinical trials were 65 years or older, with consistent pharmacokinetics and effectiveness seen across age groups in both studies.
Pediatrics
Use in children and adolescents
- Safety and efficacy in patients under 18 years of age have not been studied, and Health Canada has not authorized a pediatric indication.
Dosage & Administration
Practical dosing and administration
- The recommended dose is 25 mg given by subcutaneous injection once every 3 months.
- Vutrisiran must be administered by a healthcare professional, using the prefilled syringe in the abdomen, thigh, or upper arm.
- If stored refrigerated, the prefilled syringe should be allowed to warm to room temperature for about 30 minutes before use.
- Visually inspect the syringe and solution before injecting; do not use if the syringe is damaged or the solution is cloudy, discoloured, or contains particles.
- Avoid injecting within 5 cm of the navel, or into scar tissue or skin that is red, inflamed, or swollen.
- No dose adjustment is needed for mild or moderate hepatic or renal impairment; vutrisiran has not been studied in severe hepatic or renal impairment, or in end-stage renal disease.
- Patients switching from another TTR-reducing therapy should be monitored closely, given limited experience with switching regimens.
- There is limited data with vutrisiran in patients who have progressed to advanced heart failure (NYHA Class IV, or Class III with stage 3 ATTR amyloidosis), though these patients may remain on treatment at the physician's discretion.
- If a dose is missed, it should be given as soon as possible, with the next dose then scheduled 3 months from that administration.
Overdose
Recognizing and responding to overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- Clinical experience with vutrisiran overdose is limited, and the product monograph does not describe a specific toxidrome.
- Management involves monitoring the patient for any signs or symptoms of adverse effects and providing appropriate treatment.
Common side effects
Frequently reported tolerability concerns
- Pain in the arms, hands, legs, or feet is common.
- Joint pain (arthralgia) is common.
- Shortness of breath (dyspnea) may occur.
- Bruising at the injection site may occur.
- Redness at the injection site may occur.
- Pain at the injection site may occur.
- Itching (pruritus) at the injection site may occur.
- Warmth at the injection site may occur.
Serious side effects
Findings that may require urgent assessment
Serious side effects require immediate discussion with the prescriber or emergency care.
- Reduced vitamin A levels occur in essentially all patients due to vutrisiran's effect on TTR, which normally carries vitamin A in the blood.
- Vitamin A deficiency symptoms, including reduced night vision, persistent dry eyes, eye inflammation, corneal thickening, or corneal ulceration or perforation, can occur and warrant referral to an eye specialist.
- Standard blood tests for vitamin A do not reflect total body vitamin A and should not be used to guide supplementation while on treatment.
- A small number of patients develop anti-drug antibodies, though these have not been associated with reduced effectiveness or safety concerns.
- Seek urgent medical attention for a severe allergic reaction, or for any sudden or worsening change in vision.
Use with caution
Situations requiring closer assessment
- Daily vitamin A supplementation at the recommended daily allowance is advised for all patients taking vutrisiran, since the drug lowers blood vitamin A levels.
- Use with caution in patients with pre-existing eye disease related to amyloidosis, since it can be difficult to distinguish from vitamin A deficiency symptoms; referral to an ophthalmologist is recommended if new ocular symptoms develop.
- Women of childbearing potential should use effective contraception during treatment, given the teratogenic risk associated with unbalanced vitamin A levels.
- Serum vitamin A levels may remain reduced for more than 12 months after the last dose, which should be considered when planning a pregnancy.
- No formal studies have assessed vutrisiran's effect on the ability to drive or operate machinery, though it is not expected to have a significant effect.
Contraindications
Situations where therapy may be inappropriate
- Contraindicated in patients with a history of severe hypersensitivity to vutrisiran or to any ingredient in the formulation.
Drug interactions
Clinically relevant combinations
- No clinical drug-drug interaction studies have been performed with vutrisiran.
- Vutrisiran is not expected to cause drug interactions through cytochrome P450 enzymes or drug transporters, based on its metabolism by endonucleases and exonucleases rather than CYP pathways.
- No formal studies on drug-behavioural interactions have been performed with vutrisiran.
Food interactions
Meal-related administration
- Not applicable; vutrisiran is given by subcutaneous injection, and interactions with food have not been established for this route.
- Interactions with herbal products have not been established.
Time of administration
Practical scheduling
- Given as a subcutaneous injection by a healthcare professional once every 3 months; timing is not tied to meals or time of day.
Storage
Product handling
- Store at 2°C to 30°C in the original carton until ready for use.
- Do not freeze.
- Do not dispose of unused medicine via wastewater or household waste; ask a healthcare professional how to dispose of it safely.
Patient take-away
Key counselling points for a quick closing summary
- Vutrisiran (AMVUTTRA) is a subcutaneous injection given every 3 months by a healthcare professional to treat nerve or heart complications of transthyretin (TTR) amyloidosis.
- Daily vitamin A supplementation is needed throughout treatment because vutrisiran lowers blood vitamin A levels.
- Report any change in vision, night vision problems, or persistent dry eyes to your healthcare professional.
- Effective contraception is needed during treatment, since imbalanced vitamin A levels can harm a developing baby.
- Injection-site reactions, joint pain, and limb pain are common but usually mild.
References
Source material and product information
For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.